

CITATION REPORT

List of articles citing

The Expiry of Humira Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

DOI: 10.3389/fphar.2020.591134

Frontiers in Pharmacology, 2020, 11, 591134.

Source: <https://exaly.com/paper-pdf/82736953/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
28	Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications. <i>Medicine Access Point of Care</i> , 2021 , 5, 239920262110276	0.8	3
27	Prescribers' knowledge of drug costs: a contemporary Irish study. <i>Drugs and Therapy Perspectives</i> , 2021 , 37, 272-281	1.5	
26	Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis. <i>Frontiers in Pharmacology</i> , 2021 , 12, 644187	5.6	3
25	Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications. <i>Hospital Practice (1995)</i> , 2021 , 49, 266-272	2.2	9
24	Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 1495-1501	2.8	0
23	Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	5
22	The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. <i>Frontiers in Public Health</i> , 2021 , 9, 671961	6	9
21	Evidence-based public policy making for medicines across countries: findings and implications for the future. <i>Journal of Comparative Effectiveness Research</i> , 2021 , 10, 1019-1052	2.1	7
20	Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. <i>BioMed Research International</i> , 2021 , 2021, 9996193	3	2
19	Biologika und Biosimilars in Deutschland und im europäischen Vergleich – Marktsteuerungsmechanismen und Preisvergleich. 2021 , 75-107		2
18	Volume and trends of adalimumab and pembrolizumab reimbursed market: the Bulgarian perspective. <i>Biotechnology and Biotechnological Equipment</i> , 2021 , 35, 1778-1791	1.6	
17	A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program.. <i>Frontiers in Medicine</i> , 2022 , 9, 799494	4.9	2
16	An update on the adalimumab biosimilar landscape following the approval of the first high-concentration biosimilar. <i>Immunotherapy</i> , 2021 ,	3.8	1
15	Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab.. <i>Current Medical Research and Opinion</i> , 2022 , 1-33	2.5	1
14	Embracing Change: An International Survey Study on the Beliefs and Attitudes of Pediatric Rheumatologists Towards Biosimilars.. <i>BioDrugs</i> , 2022 , 1	7.9	
13	Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi): a multidisciplinary perspective.. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-13	5.4	0
12	Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 832215	5.6	1

11	The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland. <i>BioDrugs</i> , 2022 , 36, 537-547	7.9	○
10	Switching Among Biosimilars: A Review of Clinical Evidence. 13,		1
9	How to balance valuable innovation with affordable access to medicines in Belgium?. 13,		○
8	How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015-2021.		○
7	Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China. 13,		○
6	Introduction of managed entry agreements in Korea: Problem, policy, and politics. 14,		○
5	Überblick über Maßnahmen zur Förderung des Einsatzes von Biosimilars in europäischen Ländern. 2022 , 57-81		○
4	Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis. 14,		○
3	Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis. 1-5		○
2	Recommendations on TNF-inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance. 1-17		○
1	Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia. 1-7		○